To appraise the clinical and cost effectiveness of Osimertinib within its marketing authorisation for treating adjuvant treatment of patients with non-small cell lung cancer.
 
Status In progress
Process STA 2018
ID number 3835

Project Team

Project lead Louise Jafferally

Email enquiries

Evidence Review Group / Assessment Group School of Health and Related Research (ScHARR), University of Sheffield

Consultees

Companies sponsors AstraZeneca (osimertinib)
Others Department of Health and Social care
  NHS England
  Welsh Government
Patient carer groups EGFR Positive UK
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies None
General commentators All Wales Therapeutic and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
16 September 2021 Committee meeting: 2
05 August 2021 - 26 August 2021 Appraisal consultation
14 July 2021 Committee meeting: 1
16 December 2020 Invitation to participate
12 October 2020 - 09 November 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
01 September 2020 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance